Eli Lilly and Company (NYSE:LLY) Stock Price Up 2.1% – Should You Buy?

Shares of Eli Lilly and Company (NYSE:LLY) traded up 2.1% on Tuesday . The company traded as high as $1,232.00 and last traded at $1,222.61. Approximately 2,371,260 shares were traded during trading, a decline of 24% from the average session volume of 3,120,104 shares. The stock had previously closed at $1,197.53.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly is investing another $750 million to expand U.S. manufacturing capacity for its diabetes and obesity medicines. The Resilience expansion in Ohio is expected to add at least 400 jobs, bringing the site’s workforce above 1,400, and supports the company’s broader plan to spend approximately $55 billion on U.S. manufacturing. Lilly Boosts Diabetes and Obesity Capacity With $750 Million Deal
• Positive Sentiment: The completion of a late-stage retatrutide trial provides a potential next catalyst for Lilly’s obesity and diabetes pipeline. Investors are now awaiting study results, particularly regarding weight loss and possible cardiovascular benefits. Lilly’s Retatrutide Trial Completion Signals Next Wave in Diabetes and Obesity Drugs
• Positive Sentiment: Analyst commentary continues to emphasize Lilly’s growth profile, supported by its expanding obesity and diabetes franchises and a broader pipeline of potential medicines. Jim Cramer characterized LLY as a long-term “own, don’t trade” stock, while brokerages maintain a consensus “Moderate Buy” rating. Jim Cramer: Eli Lilly Is A Good Company
• Neutral Sentiment: Lilly’s planned $2.8 billion acquisition of AtaiBeckley would add exposure to psychedelic drug development, but the transaction is still an early-stage pipeline investment and is unlikely to materially affect near-term earnings. Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion
• Negative Sentiment: Erste Group Bank lowered its 2026 EPS forecast to $35.34 from $36.33, although the revised estimate remains above the broader consensus of $34.91. The cut may reinforce concerns that Lilly’s elevated valuation requires continued earnings upside. Analyst Earnings Estimate Update
• Negative Sentiment: Pre-earnings analysis cautions that Lilly may not have the strongest combination of estimate revisions and surprise indicators for an upcoming earnings beat, creating near-term pressure despite strong recent revenue and profit growth. Eli Lilly Earnings Expected to Grow

Analyst Upgrades and Downgrades

A number of research analysts recently commented on LLY shares. Morgan Stanley increased their price target on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Citigroup raised their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Barclays lifted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Monday, May 4th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, July 1st. Finally, Rothschild & Co Redburn raised their target price on Eli Lilly and Company from $880.00 to $900.00 in a research report on Thursday, May 7th. Two analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Eli Lilly and Company Stock Performance

The company’s 50-day moving average price is $1,148.72 and its two-hundred day moving average price is $1,042.77. The company has a market cap of $1.09 trillion, a P/E ratio of 41.07, a price-to-earnings-growth ratio of 1.52 and a beta of 0.51. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted $3.34 earnings per share. As a group, equities analysts forecast that Eli Lilly and Company will post 34.91 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Institutional Trading of Eli Lilly and Company

Several institutional investors and hedge funds have recently bought and sold shares of LLY. Ballast Inc. lifted its holdings in shares of Eli Lilly and Company by 10.9% in the second quarter. Ballast Inc. now owns 4,427 shares of the company’s stock valued at $5,310,000 after purchasing an additional 434 shares in the last quarter. Regent Peak Wealth Advisors LLC lifted its stake in Eli Lilly and Company by 4.2% in the 2nd quarter. Regent Peak Wealth Advisors LLC now owns 2,995 shares of the company’s stock worth $3,592,000 after acquiring an additional 120 shares in the last quarter. Northside Capital Management LLC boosted its position in Eli Lilly and Company by 3.0% during the 2nd quarter. Northside Capital Management LLC now owns 20,894 shares of the company’s stock worth $25,061,000 after acquiring an additional 618 shares during the period. Annex Advisory Services LLC grew its stake in Eli Lilly and Company by 1.6% during the 2nd quarter. Annex Advisory Services LLC now owns 3,835 shares of the company’s stock valued at $4,599,000 after acquiring an additional 60 shares in the last quarter. Finally, Insight Wealth Strategies LLC increased its holdings in shares of Eli Lilly and Company by 5.8% in the 2nd quarter. Insight Wealth Strategies LLC now owns 273 shares of the company’s stock valued at $325,000 after purchasing an additional 15 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.